Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZP541 in adults with irritability associated with ASD
NCT05733390Phase 2Withdrawn
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jun 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing JZP541 with Placebo (2 arms). Primary endpoint: Change From Baseline to Week 12 in the Aberrant Behavior Checklist-Irritability (ABC-I) Subscale Score. Planned start Jun 2023; status: withdrawn.
02
Drugs
JZP541
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05733390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05733390.